Stockbridge clinic

Wegovy

Evidence based, medically supported treatment that actually works
start consultation
Once weekly
Self injected medication
15-20%
Expected weight loss
Over 20 years
Of GLP-1 use worldwide

What is Wegovy?


Wegovy is a brand name for a prescription medication that contains the active ingredient semaglutide. It's primarily used for weight management in adults who are overweight or obese, and it is usually prescribed in combination with a reduced-calorie diet and increased physical activity. Wegovy works by mimicking the action of a hormone called GLP-1 (glucagon-like peptide-1), which helps regulate appetite and food intake.

The medication is administered via a weekly injection, and it helps to:
1) Increase feelings of fullness (satiety) after eating, which can reduce overall food intake.
2) Slow gastric emptying, which means food stays in the stomach longer, contributing to a feeling of fullness.
3) Decrease appetite, leading to reduced cravings.

Medical evidence


As doctors, we will only prescribe a treatment that is well evidenced to be safe and effective.

Have a look at the STEP clinical trial data of Wegovy® below. This data can been referenced entirely here if you would like to look in more detail.

Step 1 Wegovy® Trial

Summary: Alongside achievable diet and exercise changes, Wegovy® patients achieve significantly higher weight loss compared to placebo.

Step 4 Wegovy® Trial

Summary: Continued treatment with Wegovy® helps patients loose more weight and keep it off.

Step 5 Wegovy® Trial

Summary: Wegovy® patients sustain weight loss.

Safety Data

Summary: As with any drug, Wegovy® has side effects. For the vast majority of patients these side effects are manageable.

Preventative medicine

Wegovy has gained interest and coverage worldwide recently because of its effects on reducing the rate of cardiovascular events in people living with obesity.

Heart Attack Risk

SELECT TRIAL

This 5 year study found Wegovy reduced heart attack risk by 28%.

Read more

Stroke Risk

SELECT TRIAL

This 5 year study found Wegovy reduced non fatal strokes by 7%.

Read more

Diabetes Risk

STEP TRIAL

This 5 year study found Wegovy reduced diabetes risk by 60%.

Read more

Cardiac death

SELECT TRIAL

This 5 year study found Wegovy reduced heart attack risk by 18%.

Read more

Dosing Schedule

There are 5 different doses of Wegovy - usually patients spend 4 weeks at each treatment dose before increasing. Treatment doses should be carefully titrated for each patient and must be done under careful medical supervision.

0.25mg

4 weeks

0.5mg

4 weeks

1mg

4 weeks

1.7mg

4 weeks

2.4mg

Maintenance dose
The Stockbridge Clinic
Pricing
From £62.50 per week
  • Doctor face to face assessment & follow up
  • Nutritonal & Psychological Expert Support
  • Access to bespoke phone app
  • 24/7 follow up and support
  • Licensed and insured
Wegovy assessment
Start assessment

Wegovy FAQs

The most common side effects of Wegovy® may include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.

People respond to medicines differently, so there is no set time for when you can expect to see results with Wegovy®. Most patients start noticing weight changes within a few months.

It is possible to travel with your Wegovy® pen.

  • When traveling by air, keep your Wegovy® pen with you or in your carry-on, as it may freeze in the baggage compartment. Be sure to check with the airline to see if they have any specific baggage rules
  • If needed, Wegovy® may be stored between 46 °F and 86 °F in the original carton for up to 28 days

Each patient will be on the medicine for different lengths of time. The Stockbridge Clinic recommends a minimum of 6 months of treatment. 

At The Stockbridge Clinic we only prescribe on license. There is a complex assessment process and consent process for this medicine which is why we only prescribe after a face to face doctor assessment and consultation. 

Basic criteria includes BMI>27.5 with obesity related co-morbidities or BMI>30. 

Resources

NICE
BMI Calculator
NovoNordisk

Our partners

© 2025 The Stockbridge Clinic (Face Clinic Medical Ltd)
Privacy policy Terms and conditions